Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics (TM), a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

We currently have a robust clinical-stage product pipeline and multiple preclinical product candidates. Our most advanced product candidates are in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer’s disease  and cognitive dysfunction in schizophrenia.

Targacept is located in Winston-Salem, North Carolina.

On May 26, 2009, The Scientist, magazine of the life sciences, announced the winners of its 7th annual "Best Places to Work in Industry" survey and Targacept was among the award winners...more.....   Targacept has several product candidates in clinical development. View our pipeline to learn more.   Targacept is proud to support the 2010 North Carolina Science Festival, Sept. 11 – 26, 2010. The Festival is a multi-day celebration that will showcase science throughout the state, featuring hands-on activities, lab tours, science talks, exhibits, performances and more. learn more. Watch the animation to find out how our drugs work in the nervous system.

September 07, 2010 Targacept Announces Participation in Upcoming Conferences August 04, 2010 Targacept Reports Second Quarter 2010 Financial Results August 03, 2010 Targacept Makes Strategic Additions to Inflammatory Disorders Program June 23, 2010 AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214 as an Adjunct Treatment for Major Depressive Disorder May 19, 2010 Targacept Initiates Phase 2 Study of TC-5619 in Attention Deficit/Hyperactivity Disorder in Adults May 03, 2010 Targacept and AstraZeneca Agree to Expanded TC-5619 Development Program January 11, 2010 Targacept Receives $200 Million Upfront Payment from AstraZeneca December 03, 2009 AstraZeneca and Targacept Form Global Collaboration and License Agreement for Late-stage Investigational Product TC-5214 for the Treatment of Major Depressive Disorder